newsroom.

Cosette Pharmaceuticals, Inc., a U.S.-based, fully integrated, pharmaceutical company, announced today that it has entered into a definitive agreement to acquire all the outstanding shares of Mayne Pharma Group Limited (ASX: Ticker MYX) (Mayne Pharma) at AUD$7.40/share for a total consideration of approximately USD $430 Million. The Boards of Directors of both companies have approved the transaction and Mayne Pharma’s Board of Directors has unanimously recommended that its shareholders vote in favor of the transaction. The transaction is expected to close in the second quarter of 2025.

Cosette Pharmaceuticals, Inc., a leading specialty pharmaceuticals company, today announced the appointment of Brad Leonard as Vice President, Commercial Operations. In this role, Brad will spearhead Cosette’s generics business, including Generics Sales, Marketing/Pricing, Customer Service, and Demand Planning, as the company continues its expansion in these markets.

Avista Capital Partners (“Avista”), a leading New York-based private equity firm focused exclusively on healthcare, and Hamilton Lane, a leading global private markets investment management firm (Nasdaq: HLNE), today announced that funds managed by Hamilton Lane have acquired a significant equity interest in Cosette Pharmaceuticals (“Cosette”), a US-based specialty pharmaceutical company, from Avista and its co-investors.

Cosette Pharmaceuticals, Inc. (“Cosette”), a US-based specialty pharmaceutical company, has completed the acquisition of Ambien® and Ambien CR® in the United States from Sanofi US.

Cosette Pharmaceuticals, Inc. ("Cosette") announced that the U.S. Food and Drug Administration (FDA) has approved the Abbreviated New Drug Applications (ANDA) for the first generic version of RECTIV® (nitroglycerin) ointment, 0.4%, with 180 days Competitive Generic Therapy (CGT) exclusivity. Cosette will imminently commence commercial shipments, triggering the 180 days exclusivity.

We are excited to announce that our women’s healthcare portfolio has expanded with the addition of Vyleesi® (Bremelanotide Injection) from Palatin Technologies! Vyleesi® is the only FDA-Approved as-needed treatment for the approximately 6 million premenopausal women who suffer from Hypoactive Sexual Desire Disorder (HSDD). This adds another commercial stage, patent protected product to Cosette’s rapidly expanding Women’s health portfolio.

Cosette Pharmaceuticals, Inc., a New Jersey-based specialty pharmaceutical company, today announced the appointment of Ted Smolenski as Vice President, Portfolio and Business Development, bolstering its product portfolio and business development team.

We’re thrilled to announce that Apurva Saraf, our esteemed President and CEO, has been recognized with the esteemed “CEO of the Year” award by Avista Capital Partners. This remarkable achievement stands as a testament to Apurva’s exceptional leadership and the steadfast dedication of our team at Cosette Pharmaceuticals, Inc. towards driving growth and innovation.

Cosette Pharma announced today that it has entered into an agreement with Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs) to offer CLOMID® (clomiPHENE citrate) 50mg tablets at a low cash price via the Cost Plus Drugs online pharmacy.

Cosette Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved its abbreviated new drug application (ANDA) for a generic version of MetroGel-Vaginal® (metronidazole vaginal gel 0.75%) by Bausch Health US, LLC.